This review found that in people with hypertension a reduction in heart rate achieved through use of beta-blockers increased the risk of cardiovascular events and death. There were some methodological problems with the review. It was possible that confounding factors may have influenced the results and this was not investigated. The conclusions may be unreliable.
Meta-regression was used to investigate the relationship between heart rate at end of treatment with beta-blockers and risk of cardiovascular events. A weighted curve fit analysis was used to evaluate the best regression fit (p was considered significant at <0.05). Heterogeneity was assessed using the X 2 test and the I 2 statistic. Publication bias was investigated using Egger's test.
Results of the review
Nine RCTs (68,640 participants) were included: two placebo-controlled (7,984 participants) and seven active control (60,656 participants).
Tests showed no evidence of publication bias.
There was no significant difference in final blood pressure between beta-blocker and comparison group. There was a 12% lower heart rate in the beta-blocker group compared to the comparison group (p<0.0001).
There were no significant differences between beta-blockers and comparison in cardiovascular mortality (p=0.615; seven trials), non-fatal myocardial infarction (p=0.275; eight trials), heart failure (p=0.959; five trials), stroke (p=0.746, eight trials) and all-cause mortality (p=0.870, seven trials).
There was an inverse linear relationship between heart rate at end of treatment and risk of cardiovascular mortality (p=0.0001), non-fatal myocardial infarction (p=0.0001), heart failure (p=0.0001), stroke (p=0.0602) and all cause mortality (p=0.0000001), which indicated that relative risk increased as heart rate decreased.
Authors' conclusions
Beta-blocker associated reduction in heart rate increased the risk of cardiovascular events and death in hypertensive people.
CRD commentary
The aims of this review were clearly defined in terms of inclusion criteria for study design, intervention and participants. A number of databases were searched. As studies other than published English-languages studies were excluded, it was possible that studies were missed. The method of data extraction was not described, so it was impossible to say whether steps were taken to reduce reviewer error or bias. The quality of the included studies did not appear to be assessed, so the reliability of data was unclear. The authors pooled outcomes from studies that compared different treatments (such as placebo-controlled trials and trials that used other hypertensive agents as the comparison), which may not have been appropriate. The authors conclusions regarding heart rate and cardiovascular events were based on comparisons between studies in which characteristics of participants and treatments appear to have varied. Therefore, it was possible that other confounding factors may have influenced the results. As the authors commented, most participants received atenolol as the beta-blocker and it may not be appropriate to generalise these results to other beta-blockers. Given these comments, the conclusions should be interpreted with caution and may be unreliable.
Implications of the review for practice and research
Practice: The authors did not state any implications for practice.
Research: The authors stated that further research was needed to establish the cause of the association between a decrease in heart rate (related to beta-blocker use) and risk of cardiovascular events.
